A5041016511- Multiple Sclerosis Research Studies
- Cannabis and Cannabinoid Research
- Health Systems, Economic Evaluations, Quality of Life
- Parkinson's Disease Mechanisms and Treatments
- Dementia and Cognitive Impairment Research
- Cerebral Palsy and Movement Disorders
- Systemic Sclerosis and Related Diseases
- Neuroscience and Neuropharmacology Research
- Toxin Mechanisms and Immunotoxins
- Peripheral Neuropathies and Disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurogenesis and neuroplasticity mechanisms
- Polyomavirus and related diseases
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Sarcoidosis and Beryllium Toxicity Research
- Rheumatoid Arthritis Research and Therapies
- Immunotherapy and Immune Responses
- Prion Diseases and Protein Misfolding
- Botulinum Toxin and Related Neurological Disorders
- Alzheimer's disease research and treatments
- Ginkgo biloba and Cashew Applications
- Health, Environment, Cognitive Aging
- Neurological disorders and treatments
- Nuclear Receptors and Signaling
University of St Andrews
2015-2022
University of Plymouth
2004-2018
Peninsula College
2018
Peninsula College of Medicine and Dentistry
2005-2015
Pfizer (United States)
2013
University of California, San Diego
2012
Addenbrooke's Hospital
1990-2011
University of Cambridge
1981-2011
University of Exeter
2011
University of Liverpool
2010-2011
A series of 68 patients with neurosarcoidosis is reported, particular emphasis on clinical aspects, diagnosis and treatment. classification system based diagnostic probability proposed, consisting probable definite disease, the latter being dependent finding sarcoid granulomas nervous histology, which was obtained in 12 (18%). The role investigations, including magnetic resonance imaging (MRI), chest radiography, Kveim skin test, Gallium 67 isotope scanning cerebrospinal fluid (CSF) studies,...
Multiple sclerosis (MS) is associated with chronic symptoms, including muscle stiffness, spasms, pain and insomnia. Here we report the results of Sclerosis Extract Cannabis (MUSEC) study that aimed to substantiate patient based findings previous studies.Patients stable MS at 22 UK centres were randomised oral cannabis extract (CE) (N=144) or placebo (N=135), stratified by centre, walking ability use antispastic medication. This double blind, controlled, phase III had a screening period, 2...
In June 1999, the Association of British Neurologists (ABN) first published guidelines for use licensed multiple sclerosis (MS) disease-modifying treatments (at that time β-interferon and glatiramer acetate). The were revised in 2001 have been periodically updated since then. 2002, following negative assessment these by National Institute Health Care Excellence (NICE), MS risk-sharing scheme started, which patients eligible according to ABN provided with treatment funded through UK Service...
To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), a follow up to main Cannabinoids Multiple Sclerosis (CAMS) study.In total, 630 patients with stable MS muscle spasticity from 33 UK centres were randomised receive oral Delta(9)-tetrahydrocannabinol (Delta(9)-THC), cannabis extract, or placebo 15 week CAMS study. The primary outcome was change Ashworth scale. Secondary outcomes Rivermead Mobility Index, timed 10 metre walk, Neurological Disability...
<b><i>Background:</i></b> The long-term treatment of Parkinson disease (PD) may be complicated by the development levodopa-induced dyskinesia. Clinical and animal model data support view that modulation cannabinoid function exert an antidyskinetic effect. authors conducted a randomized, double-blind, placebo-controlled crossover trial to examine hypothesis cannabis have beneficial effect on dyskinesia in PD. <b><i>Methods:</i></b> A 4-week dose escalation study was performed assess safety...
<h3>Objective:</h3> To define the rate, timing, and clinical risk factors for development of autoimmune disease (AID) after alemtuzumab treatment multiple sclerosis (MS). <h3>Methods:</h3> We analyzed prospective serologic data from 248 patients with MS treated alemtuzumab, median follow-up 34.3 months (range 6.7–107.3). <h3>Results:</h3> Novel AID developed in 22.2%. Thyroid was most frequent (15.7%). A range hematologic, renal, dermatologic were also observed as asymptomatic novel...
Interactions between rat microglia and oligodendrocytes were examined in vitro order to characterize the stages of adherence, phagocytosis cytotoxicity against by microglia. Under resting conditions, showed minimal contact with exhibited surface staining myelin basic protein debris only; they not cytotoxic for did produce tumour necrosis factor (TNF). On activation either Γ-interferon or lipopolysaccharide interferon, these cells increased binding protein, greater living produced TNF both...
Interactions between rat microglia and oligodendrocytes were examined in vitro order to characterize the stages of adherence, phagocytosis cytotoxicity against by microglia. Under resting conditions, showed minimal contact with exhibited surface staining myelin basic protein debris only; they not cytotoxic for did produce tumour necrosis factor (TNF). On activation either Γ-interferon or lipopolysaccharide interferon, these cells increased binding protein, greater living produced TNF both...
<b><i>Background:</i></b> Disabling tremor is common in patients with multiple sclerosis (MS). Data from animal model experiments and subjective small objective studies involving suggest that cannabis may be an effective treatment for associated MS. To our knowledge, there are no published double-blind randomized controlled trials of as a MS patients. <b><i>Methods:</i></b> The authors conducted placebo-controlled crossover trial to examine the effect oral cannador (cannabis extract) on 14...
Δ⁹-tetrahydrocannabinol (Δ⁹-THC) is neuroprotective in models of Parkinson's disease (PD). Although CB1 receptors are increased within the basal ganglia PD patients and animal models, current evidence suggests a role for receptor-independent mechanisms. Here, we utilized human neuronal cell culture model to further investigate protective properties Δ⁹-THC.Differentiated SH-SY5Y neuroblastoma cells were exposed PD-relevant toxins: 1-methyl-4-phenylpyridinium (MPP+), lactacystin paraquat....
Diagnosis of Alzheimer's disease (AD) is often difficult, especially early in the process at stage mild cognitive impairment (MCI). Yet, it this that treatment most likely to be effective, so there would great advantages improving diagnosis process. We describe and test a machine learning approach for personalized cost-effective AD. It uses locally weighted tailor classifier model each patient computes sequence biomarkers informative or diagnose patients. Using ADNI data, we classified AD...
Background The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ 9 -tetrahydrocannabinol (Δ -THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety cannabinoid administration; and, improve methods for testing treatments MS. Objectives There were three objectives CUPID study: (1) -THC could slow MS; (2) assess long-term -THC; and (3) explore newer ways conducting clinical trials Design was a randomised,...
Current treatments manage symptoms of Parkinson disease (PD), but no known treatment slows progression. Preclinical and epidemiological studies support the potential use statins as disease-modifying therapy.